论文部分内容阅读
目的比较缬沙坦和替米沙坦治疗老年高血压的疗效及安全性。方法将60例中度老年高血压患者随机均分为两组,分别采用缬沙坦80~160mg和替米沙坦40~80mg每日晨起顿服。监测两组治疗前和治疗4周后BP、空腹血糖、血脂、肾功能、电解质和心电图的变化,观察不良反应发生情况。结果缬沙坦组BP从(162.20±6.26)/(84.73±8.00)mmHg降到(138.13±7.50)/(77.60±7.91)mmHg(P<0.01),替米沙坦组从(161.30±6.20)/(85.47±7.64)mmHg降到(143.50±6.62)/(79.30±7.57)mmHg(P<0.01),缬沙坦组降压幅度较替米沙坦组稍高(P>0.05)。治疗前后两组空腹血糖、血脂、肾功能、电解质水平及心电图均无明显变化。缬沙坦组不良反应发生率低于替米沙坦组(6.7%vs.20.0%)(P<0.05)。结论缬沙坦较替米沙坦治疗老年高血压更安全、有效。
Objective To compare the efficacy and safety of valsartan and telmisartan in the treatment of elderly patients with hypertension. Methods Sixty middle-aged hypertensive patients were randomly divided into two groups: valsartan 80 ~ 160mg and telmisartan 40 ~ 80mg, respectively. The changes of BP, fasting blood glucose, blood lipid, renal function, electrolytes and electrocardiogram were observed before treatment and after 4 weeks of treatment, and the incidence of adverse reactions was observed. Results BP decreased from (162.20 ± 6.26) / (84.73 ± 8.00) mmHg to (138.13 ± 7.50) / (77.60 ± 7.91) mmHg in valsartan group and (161.30 ± 6.20) /(85.47 ± 7.64)mmHg to (143.50 ± 6.62) / (79.30 ± 7.57) mmHg (P <0.01). The depressurization rate in valsartan group was slightly higher than that in telmisartan group (P> 0.05). Before and after treatment, fasting blood glucose, blood lipid, renal function, electrolytes and ECG had no significant changes. The incidence of adverse reactions in the valsartan group was lower than that in the telmisartan group (6.7% vs. 20.0%, P <0.05). Conclusion Valsartan is more safe and effective than telmisartan in treating elderly hypertension.